SCHEMBL21593371

SCHEMBL21593371

COc1cc(Br)cc2c1C(=O)N(CC#N)CC2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIK2 Q9H0K1 8/20 0.45
SIK1 P57059 1/20 0.45
SIK3 Q9Y2K2 1/20 0.45
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
TUBB4A P04350 1/20 0.36
TUBB P07437 1/20 0.36
TUBA3C P0DPH7 1/20 0.36
TUBA1B P68363 1/20 0.36
TUBA4A P68366 1/20 0.36
TUBB4B P68371 1/20 0.36
TUBB3 Q13509 1/20 0.36
TUBB2A Q13885 1/20 0.36
TUBB8 Q3ZCM7 1/20 0.36
TUBA3E Q6PEY2 1/20 0.36
TUBA1A Q71U36 1/20 0.36
TUBA1C Q9BQE3 1/20 0.36
TUBB6 Q9BUF5 1/20 0.36
TUBB2B Q9BVA1 1/20 0.36
TUBB1 Q9H4B7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21593328 0.85 SIK2 (0.41) SIK2MEN1KMT2AEZH2GAA
SCHEMBL32691424 0.84 SIK2 (0.36) SIK2SIK1SIK3
SCHEMBL30903189 0.84 DRD4 (0.39) SIK2MEN1KMT2AEZH2DRD2
SCHEMBL21593330 0.81 SIK2 (0.58) SIK2SIK1SIK3MEN1KMT2A
SCHEMBL21593443 0.81 SIK2 (0.41) SIK2SIK1SIK3MEN1KMT2A
SCHEMBL21593345 0.81 GRM5 (0.42) SIK2MEN1KMT2AEZH2GAA
SCHEMBL28597676 0.81 MEN1 (0.55) MEN1KMT2ATUBB4ATUBBTUBA3C
SCHEMBL32691408 0.80 SIK1 (0.32) SIK2SIK1SIK3DRD2
SCHEMBL32691557 0.79 GRM5 (0.47) SIK2KMT2AEZH2
SCHEMBL32691499 0.77 SIK2 (0.42) SIK2SIK1SIK3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724431-A1 BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND USE THEREOF Beone Medicines I GmbH (CH) 2026-04-15 EP disclosed
US-20260085053-A1 BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND THE USE THEREOF BEONE MEDICINES I GMBH (CH) 2026-03-26 US disclosed
EP-4619397-A1 SALT-INDUCIBLE KINASES (SIK) INHIBITORS AND METHODS OF USES THEREOF Insilico Medicine IP Limited (HK) 2025-09-24 EP disclosed
US-12264156-B2 Compounds and pharmaceutical compositions thereof for the treatment of diseases GALAPAGOS NV (BE) 2025-04-01 US disclosed
US-20220402911-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2022-12-22 US disclosed
US-20220402911-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2022-12-22 US disclosed
WO-2019238424-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2019-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260085053-A1 BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND THE USE THEREOF SIK1, CHUK, SIK2 SIK2 3/4885SIK1 1/4885SIK3 5/4885
US-20220402911-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES IL1A, TNF, IL6 SIK2 4381/4885SIK1 3905/4885SIK3 3390/4885
US-12264156-B2 Compounds and pharmaceutical compositions thereof for the treatment of diseases TNF, IL1A, COL1A1 SIK2 4373/4885SIK1 3832/4885SIK3 3341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.